XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
I
I

Ipsen


Actualités

Ipsen, Foreseen Biotechnology Enter Licensing Agreement For Antibody-Drug Conjugate

BRIEF-Ipsen, Foreseen Biotechnology Enter Licensing Agreement For Antibody-Drug Conjugate July 11 (Reuters) - Ipsen SA IPN.PA : IPSEN AND FORESEEN BIOTECHNOLOGY ANNOUNCE EXCLUSIVE GLOBAL LICENSING AGREEMENT FOR ANTIBODY-DRUG CONJUGATE WITH FIRST-IN-CLASS POTENTIAL EXCLUSIVE GLOBAL RIGHTS SECURED FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF
I

Pearson, Softcat, Trelleborg

EUROPE RESEARCH ROUNDUP- Pearson, Softcat, Trelleborg July 5 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Pearson, Softcat and Trelleborg, on Friday. HIGHLIGHTS * Aker BP ASA AKRBP.OL : Jefferies cuts target price to NOK 340 from NOK 345 * GSK GSK.L : Citigroup cuts target price to 1900p from 2120p * Pearson PSON.L : Deutsche Bank raises target price to 1052p from 1050p * Softcat Plc SCTS.L : Jefferies cuts target price to 1,490p
A
A
B
C
C
D
D
E
E
G
I
K
N
N
P
T
T
T
V
W
A
D
Y

Ipsen To Seek Marketing Authorizations For Cabometyx Outside Of U.S., Japan

BRIEF-Ipsen To Seek Marketing Authorizations For Cabometyx Outside Of U.S., Japan July 2 (Reuters) - Ipsen SA IPN.PA : IPSEN EXPANDS COLLABORATION AND LICENSE AGREEMENT FOR DEVELOPMENT OF CABOMETYX IN ADVANCED NEUROENDOCRINE TUMORS BASED ON POSITIVE CABINET PHASE III TRIAL DECISION ADDS TO EXISTING COLLABORATION AGREEMENT WITH EXELIXIS, PERMITTING IPSEN TO SEEK POTENTIAL MARKETING AUTHORIZATIONS FOR CABOMETYX OUTSIDE OF U.S.
I

Ipsen’S Iqirvo® Receives U.S. FDA Accelerated Approval As A First-In-Class Ppar Treatment For Primary Biliary Cholangitis

BRIEF-Ipsen’S Iqirvo® Receives U.S. FDA Accelerated Approval As A First-In-Class Ppar Treatment For Primary Biliary Cholangitis Ipsen SA IPN.PA : IPSEN’S IQIRVO® RECEIVES U.S. FDA ACCELERATED APPROVAL AS A FIRST-IN-CLASS PPAR TREATMENT FOR PRIMARY BILIARY CHOLANGITIS IPSEN SA - IQIRVO MAY BE PRESCRIBED IMMEDIATELY IN U.S. FOR ELIGIBLE PATIENTS.
I

US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug

UPDATE 3-US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug Adds details on pricing in paragraph 3, background throughout By Puyaan Singh and Mariam Sunny June 10 (Reuters) - The U.S. Food and Drug Administration granted accelerated approval to French drugmakers Ipsen IPN.PA and Genfit's GNFT.PA drug for a chronic inflammatory liver disease, Iqirvo, the companies said on Monday.
G
I

US FDA approves Genfit and Ipsen's liver disease drug

US FDA approves Genfit and Ipsen's liver disease drug June 10 (Reuters) - The U.S. Food and Drug Administration has approved French drugmakers Ipsen IPN.PA and Genfit's GNFT.PA drug to treat a chronic inflammatory liver disease, Ipsen said on Monday. Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona
I

Ipsen Initiates Share Buy-Back Program

BRIEF-Ipsen Initiates Share Buy-Back Program June 3 (Reuters) - Ipsen SA IPN.PA : IPSEN INITIATES A SHARE BUY-BACK PROGRAM TO COVER ITS FREE EMPLOYEE SHARE-ALLOCATION PLAN IPSEN APPOINTED AN INVESTMENT-SERVICES PROVIDER TO PURCHASE AN AGGREGATE NUMBER OF IPSEN S.A. SHARES UP TO 400,000, OR ABOUT 0.47% OF SHARE CAPITAL HAS APPOINTED AN INVESTMENT-SERVICES PROVIDER TO PURCHASE AN AGGREGATE NUMBER OF IPSEN S.A.
I

Genfit Q1 Revenue Falls to EUR 1.1 Million

BRIEF-Genfit Q1 Revenue Falls to EUR 1.1 Million May 15 (Reuters) - Genfit SA GNFT.PA : REPORTED ON TUESDAY FIRST QUARTER 2024 FINANCIAL INFORMATION REVENUES FOR FIRST THREE MONTHS OF 2024 AMOUNTED TO EUR 1.1 MILLION COMPARED TO EUR 5.0 MILLION FOR SAME PERIOD IN 2023 AS OF MARCH 31, 2024, CO’S CASH AND CASH EQUIVALENTS AMOUNTED TO EUR 74.0 MLN V
I

Alfa Laval, OMV AG, Unilever Plc

EUROPE RESEARCH ROUNDUP- Alfa Laval, OMV AG, Unilever Plc May 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfa Laval, OMV AG and Unilever Plc, on Tuesday. HIGHLIGHTS * Alfa Laval ALFA.ST : JP Morgan raises target price to SEK 385 from SEK 325 * Babcock International BAB.L : Citigroup raises target price to 640p from 530p * OMV AG OMVV.VI : Morgan Stanley raises to equal weight from underweight * SKAN Group AG SKAN.S : Baader
A
A
A
B
C
C
D
F
G
H
I
I
I
L
M
O
O
P
S
S
S
T
A
B
B
D
J
P

Adidas, EFG International, Smith & Nephew

EUROPE RESEARCH ROUNDUP-Adidas, EFG International, Smith & Nephew May 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas, EFG International, and Smith & Nephew, on Thursday. HIGHLIGHTS * Adidas AG ADSGn.DE : Barclays raises target price to EUR 243 from EUR 231 * EFG International AG EFGN.S : Citigroup raises to buy from neutral * Gsk GSK.L : JP Morgan raises target price to 1660p from 1530p * Kemira Oyj KEMIRA.HE : Berenberg
3
A
A
A
C
E
E
G
H
H
H
I
K
L
M
N
P
S
T
W
A
J
P
T

Ipsen Appoints Keira Driansky As EVP, President Of North America

BRIEF-Ipsen Appoints Keira Driansky As EVP, President Of North America May 2 (Reuters) - Ipsen SA IPN.PA : IPSEN APPOINTS KEIRA DRIANSKY AS EVP, PRESIDENT OF NORTH AMERICA Source text for Eikon: ID:nGNEbS43ZY Further company coverage: IPN.PA (Gdansk Newsroom)
I

Barclays, JD Sports, Renault

EUROPE RESEARCH ROUNDUP- Barclays, JD Sports, Renault April 29 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Barclays, JD Sports and Renault, on Monday. HIGHLIGHTS * Barclays BARC.L : RBC raises target price to 260p from 255p * Hexagon HEXAb.ST : Morgan Stanley raises target price to SEK 105 from SEK 101 * JD Sports JD.L : Barclays cuts to equal weight from overweight * Renault RENA.PA : Berenberg raises target price to EUR 55 fr
A
A
A
A
B
B
C
C
C
D
D
E
E
E
E
G
H
I
I
J
N
P
R
S
S
S
W
A
A
E
S

Ipsen rises after cancer treatment drives Q1 beat

BUZZ-Ipsen rises after cancer treatment drives Q1 beat ** Shares in Ipsen IPN.PA rise 3.2 % after the French biopharma company beat sales expectations in Q1 helped by its anti-cancer drug Cabometyx ** Q1 sales rise 13.3% in constant exchange rates to 822.4 million euros ($878.82 million), which Jefferies says is 4% ahead of consensus ** " Most key
I

Ipsen Confirms Financial Guidance For 2024

BRIEF-Ipsen Confirms Financial Guidance For 2024 April 24 (Reuters) - Ipsen SA IPN.PA : CONFIRMATION OF FINANCIAL GUIDANCE FOR 2024 Q1 TOTAL-SALES GROWTH OF 13.3% AT CER(1), OR 10.9% AS REPORTED, DRIVEN BY 16.2%(1) INCREASE IN SALES OF GROWTH PLATFORMS Source text for Eikon: ID:nGNE5jc9nG Further company coverage: IPN.PA (Gdansk Newsroom)
I



Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques